Live Breaking News & Updates on Caffreym Trastuzumab

Stay updated with breaking news from Caffreym trastuzumab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Trastuzumab Deruxtecan Effective For HR-Positive, HER2-Low Breast Cancer Treatment After Endocrine Therapy

Findings from ASCO 2024 suggest deruxtecan (T-DXd) may become a preferred first-line treatment for patients with hormone receptor (HR)-positive, HER2-low metastatic breast cancer that progressed after endocrine therapy. ....

Chicago , Illinois , United-states , Milano , Lombardia , Italy , American , Erical-mayer , Caffreym-trastuzumab , Daiichi-sankyo , Giuseppe-curigliano , Astrazeneca

Destiny-Breast06 Results Offer New Hope for Patients With HR-Positive, HER2-Low Metastatic Breast Cancer

Trial results from DESTINY-Breast06 indicate the effectiveness of fam-trastuzumab deruxtecan-nxki in delaying disease progression for patients with hormone receptor (HR)–positive and HER2-low metastatic breast cancer who had prior endocrine therapy. ....

United-states , Texas , American , Sebastian-kaulitzki , Susan-galbraith , Caffreym-trastuzumab , Debra-patt , Daiichi-sankyo , American-society-of-clinical-oncology , Us-food-drug-administration , Astrazeneca , Image-credit

FDA Accepts BLA for Datopotamab Deruxtecan for Nonsquamous NSCLC

The application is based on results of the phase 3 TROPION-Lung01 trial of datopotamab deruxtecan in nonsquamous non–small cell lung cancer (NSCLC), first presented at the 2023 European Society for Medical Oncology Congress. ....

California , United-states , American , Caffreym-trastuzumab , Daiichi-sankyo , Los-angeles , Susan-galbraith , Aaron-lisberg , University-of-california , Astrazeneca , European-society-for-medical-oncology , Medical-oncology

Patt Highlights Payer, Education Considerations in Trastuzumab Deruxtecan Use for HER2-Low Breast Cancer

At Patient-Centered Oncology Care®, Debra Patt, MD, PhD, MBA, of Texas Oncology, discussed managed care considerations that arise from the groundbreaking DESTINY-Breast04 study presented earlier this year. ....

Tennessee , United-states , Texas , American , Caffreym-trastuzumab , Debra-patt , Astrazeneca , College-of-american-pathologists , American-society-of-clinical-oncology , American-society , Clinical-oncology , Texas-oncology